ReviewFrontiers in immunology2025
Death as rebirth: how efferocytosis drives tissue repair and disease treatment.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efferocytosis is a crucial process by which apoptotic cells are removed by phagocytes such as macrophages. It not only maintains tissue homeostasis and immune tolerance, but also plays a central role in tissue repair and disease regulation. In recent years, dysfunction of efferocytosis has been found to be closely related to various diseases, such as atherosclerosis, cancer, and chronic inflammatory conditions. Activating or remodeling efferocytosis has become a key direction in regenerative medicine and precision therapy. This review systematically summarizes the molecular mechanisms and immunomodulatory functions of efferocytosis, highlights its roles in various models of tissue injury and repair, and explores recent advances in targeted modulation of efferocytosis using nanomaterials, biomaterial scaffolds, and hydrogels. By focusing on the biological logic of "life from death," this article aims to provide a theoretical foundation and strategic support for the translational applications of efferocytosis in tissue engineering, immunotherapy, and disease intervention. Furthermore, it highlights the synergistic potential of combining nanomaterials, hydrogels, and biological scaffolds to create next-generation efferocytosis-driven therapies, thereby offering a multidisciplinary perspective on overcoming current challenges in clinical translation. Specifically, this synergistic strategy holds particular promise in addressing key clinical challenges such as overcoming tumor immunosuppression and promoting vascularization in chronic wounds, providing a targeted approach to enhance therapeutic outcomes in these complex pathological contexts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.